<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: A growing number of patients with advanced <z:hpo ids='HP_0001635'>heart failure</z:hpo> fulfill a primary-prevention indication for an implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>This study seeks to identify new predictors of overall mortality in a <z:hpo ids='HP_0001645'>Sudden Cardiac Death</z:hpo> in <z:hpo ids='HP_0001635'>Heart Failure</z:hpo> Trial (SCD-HeFT)-like collective to enhance risk stratification </plain></SENT>
<SENT sid="2" pm="."><plain>HYPOTHESIS: An <z:hpo ids='HP_0000082'>impaired renal function</z:hpo> and severely depressed left ventricular ejection fraction pose relevant risk factors for mortality in primary prevention <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> recipients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Ninety-four consecutive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> patients with New York Heart Association class II-III <z:hpo ids='HP_0001635'>heart failure</z:hpo> and depressed left ventricular function (left ventricular ejection fraction [LVEF] ≤ 35%) with no history of malignant <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> were followed for 34 ± 20 months </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: During this period, 30 patients died (32%) </plain></SENT>
<SENT sid="5" pm="."><plain>Deceased patients revealed a significantly worse renal function before <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation (1.55 ± 0.7 mg/dL vs 1.1 ± 0.4 mg/dL; P = 0.007), suffered more often from <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (53 vs 29; P = 0.006), and were older (69.5 ± 8 y vs 67 ± 12 y; P = 0.0002) than surviving patients </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, <z:hpo ids='HP_0003259'>increased serum creatinine</z:hpo> at baseline (2 mg/dL vs 1 mg/dL; odds ratio [OR]: 3.96, 95% confidence interval [CI]: 1.2-13.04, P = 0.02), presence of <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (OR: 8.6, 95% CI: 1.1-65, P = 0.036), and low LVEF (OR per 5% baseline LVEF deterioration: 1.4, 95% CI: 1-1.8, P = 0.034) represented strong and independent predictors for overall mortality </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0000082'>Impaired renal function</z:hpo>, the presence of <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, and reduced LVEF before implantation represent independent predictors for mortality in a cohort of patients with advanced systolic <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>These conditions still bear a high mortality risk, even if <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation effectively prevents sudden arrhythmic <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Indeed, in patients suffering from several of the identified "high-risk" comorbidities, primary-prevention <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation might have a limited survival benefit </plain></SENT>
<SENT sid="10" pm="."><plain>The possible adverse effects of these comorbidities should be openly discussed with the potential <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> recipient and his or her close relatives </plain></SENT>
</text></document>